Special Issue "Biomarker in Metastatic Colorectal Cancer"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 20248
2. German Cancer Consortium (DKTK), Heidelberg, im Neuenheimer Feld 280, 69120 Heidelberg, Germany
Interests: translational oncology; metastasis research, biomarker identification and analysis; cancer signaling; cancer therapy
Interests: translational oncology; metastasis research; in vitro and in vivo cancer models; pre-clinical drug development and testing
Colorectal cancer is a cancer entity with high incidence. Metastasis represents the most lethal attribute of CRC, limiting successful therapy. Biomarkers identifying cancer patients at high risk for metastasis and simultaneously acting as key drivers for metastasis are extremely desired. Clinical interventions targeting these key molecules will result in efficient metastasis intervention and patient-tailored therapy. The fact that 40–50% of all patients newly diagnosed with CRC without distant metastases (stages I–III) will develop distant metastasis metachronously defines the clinical need for improved diagnosis and novel therapeutic options for metastasis intervention.
We are pleased to invite you to contribute original research articles and reviews to this Special Issue, which aims to highlight the research as well as clinical activities for discovery and consolidation of biomarkers of metastatic CRC, which may also serve as targets for specific therapies in metastatic CRC. Aspects of early diagnosis for metastasis detection, the identification of gene signatures and their use for the design of novel, individualized therapies, and translation into pre-clinical as well as clinical applications will be covered in this Special Issue.
We very much look forward to receiving your contribution.
Prof. Dr. Ulrike Stein
Prof. Dr. Wolfgang Walther
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- colorectal cancer